Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers
Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Brunner, G. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1988 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Drugs - Berlin [u.a.] : Springer, 1971, 35(1988), Suppl 3 vom: März, Seite 102-105 |
|---|---|
| Übergeordnetes Werk: |
volume:35 ; year:1988 ; number:Suppl 3 ; month:03 ; pages:102-105 |
| Links: |
|---|
| DOI / URN: |
10.2165/00003495-198800353-00018 |
|---|
| Katalog-ID: |
SPR033150176 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033150176 | ||
| 003 | DE-627 | ||
| 005 | 20230519101046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1988 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00003495-198800353-00018 |2 doi | |
| 035 | |a (DE-627)SPR033150176 | ||
| 035 | |a (SPR)00003495-198800353-00018-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Brunner, G. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers |
| 264 | 1 | |c 1988 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. | ||
| 650 | 4 | |a Duodenal Ulcer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ranitidine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ulcer Recurrence |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Roxatidine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Duodenal Ulcer Patient |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Berlin [u.a.] : Springer, 1971 |g 35(1988), Suppl 3 vom: März, Seite 102-105 |w (DE-627)320609413 |w (DE-600)2021165-X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:1988 |g number:Suppl 3 |g month:03 |g pages:102-105 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00003495-198800353-00018 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 35 |j 1988 |e Suppl 3 |c 03 |h 102-105 | ||
| author_variant |
g b gb |
|---|---|
| matchkey_str |
article:11791950:1988----::oaiiecttiteogemaneaco |
| hierarchy_sort_str |
1988 |
| bklnumber |
44.40 44.38 |
| publishDate |
1988 |
| allfields |
10.2165/00003495-198800353-00018 doi (DE-627)SPR033150176 (SPR)00003495-198800353-00018-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Brunner, G. verfasserin aut Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers 1988 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. Duodenal Ulcer (dpeaa)DE-He213 Ranitidine (dpeaa)DE-He213 Ulcer Recurrence (dpeaa)DE-He213 Roxatidine (dpeaa)DE-He213 Duodenal Ulcer Patient (dpeaa)DE-He213 Enthalten in Drugs Berlin [u.a.] : Springer, 1971 35(1988), Suppl 3 vom: März, Seite 102-105 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 https://dx.doi.org/10.2165/00003495-198800353-00018 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 35 1988 Suppl 3 03 102-105 |
| spelling |
10.2165/00003495-198800353-00018 doi (DE-627)SPR033150176 (SPR)00003495-198800353-00018-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Brunner, G. verfasserin aut Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers 1988 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. Duodenal Ulcer (dpeaa)DE-He213 Ranitidine (dpeaa)DE-He213 Ulcer Recurrence (dpeaa)DE-He213 Roxatidine (dpeaa)DE-He213 Duodenal Ulcer Patient (dpeaa)DE-He213 Enthalten in Drugs Berlin [u.a.] : Springer, 1971 35(1988), Suppl 3 vom: März, Seite 102-105 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 https://dx.doi.org/10.2165/00003495-198800353-00018 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 35 1988 Suppl 3 03 102-105 |
| allfields_unstemmed |
10.2165/00003495-198800353-00018 doi (DE-627)SPR033150176 (SPR)00003495-198800353-00018-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Brunner, G. verfasserin aut Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers 1988 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. Duodenal Ulcer (dpeaa)DE-He213 Ranitidine (dpeaa)DE-He213 Ulcer Recurrence (dpeaa)DE-He213 Roxatidine (dpeaa)DE-He213 Duodenal Ulcer Patient (dpeaa)DE-He213 Enthalten in Drugs Berlin [u.a.] : Springer, 1971 35(1988), Suppl 3 vom: März, Seite 102-105 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 https://dx.doi.org/10.2165/00003495-198800353-00018 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 35 1988 Suppl 3 03 102-105 |
| allfieldsGer |
10.2165/00003495-198800353-00018 doi (DE-627)SPR033150176 (SPR)00003495-198800353-00018-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Brunner, G. verfasserin aut Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers 1988 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. Duodenal Ulcer (dpeaa)DE-He213 Ranitidine (dpeaa)DE-He213 Ulcer Recurrence (dpeaa)DE-He213 Roxatidine (dpeaa)DE-He213 Duodenal Ulcer Patient (dpeaa)DE-He213 Enthalten in Drugs Berlin [u.a.] : Springer, 1971 35(1988), Suppl 3 vom: März, Seite 102-105 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 https://dx.doi.org/10.2165/00003495-198800353-00018 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 35 1988 Suppl 3 03 102-105 |
| allfieldsSound |
10.2165/00003495-198800353-00018 doi (DE-627)SPR033150176 (SPR)00003495-198800353-00018-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl 44.38 bkl Brunner, G. verfasserin aut Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers 1988 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. Duodenal Ulcer (dpeaa)DE-He213 Ranitidine (dpeaa)DE-He213 Ulcer Recurrence (dpeaa)DE-He213 Roxatidine (dpeaa)DE-He213 Duodenal Ulcer Patient (dpeaa)DE-He213 Enthalten in Drugs Berlin [u.a.] : Springer, 1971 35(1988), Suppl 3 vom: März, Seite 102-105 (DE-627)320609413 (DE-600)2021165-X 1179-1950 nnns volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 https://dx.doi.org/10.2165/00003495-198800353-00018 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE 44.38 ASE AR 35 1988 Suppl 3 03 102-105 |
| language |
English |
| source |
Enthalten in Drugs 35(1988), Suppl 3 vom: März, Seite 102-105 volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 |
| sourceStr |
Enthalten in Drugs 35(1988), Suppl 3 vom: März, Seite 102-105 volume:35 year:1988 number:Suppl 3 month:03 pages:102-105 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Duodenal Ulcer Ranitidine Ulcer Recurrence Roxatidine Duodenal Ulcer Patient |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Drugs |
| authorswithroles_txt_mv |
Brunner, G. @@aut@@ |
| publishDateDaySort_date |
1988-03-01T00:00:00Z |
| hierarchy_top_id |
320609413 |
| dewey-sort |
3610 |
| id |
SPR033150176 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033150176</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519101046.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1988 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003495-198800353-00018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033150176</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003495-198800353-00018-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brunner, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1988</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Duodenal Ulcer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ranitidine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ulcer Recurrence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Roxatidine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Duodenal Ulcer Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1971</subfield><subfield code="g">35(1988), Suppl 3 vom: März, Seite 102-105</subfield><subfield code="w">(DE-627)320609413</subfield><subfield code="w">(DE-600)2021165-X</subfield><subfield code="x">1179-1950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:1988</subfield><subfield code="g">number:Suppl 3</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:102-105</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003495-198800353-00018</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">1988</subfield><subfield code="e">Suppl 3</subfield><subfield code="c">03</subfield><subfield code="h">102-105</subfield></datafield></record></collection>
|
| author |
Brunner, G. |
| spellingShingle |
Brunner, G. ddc 610 bkl 44.40 bkl 44.38 misc Duodenal Ulcer misc Ranitidine misc Ulcer Recurrence misc Roxatidine misc Duodenal Ulcer Patient Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers |
| authorStr |
Brunner, G. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)320609413 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-1950 |
| topic_title |
610 ASE 44.40 bkl 44.38 bkl Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers Duodenal Ulcer (dpeaa)DE-He213 Ranitidine (dpeaa)DE-He213 Ulcer Recurrence (dpeaa)DE-He213 Roxatidine (dpeaa)DE-He213 Duodenal Ulcer Patient (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.40 bkl 44.38 misc Duodenal Ulcer misc Ranitidine misc Ulcer Recurrence misc Roxatidine misc Duodenal Ulcer Patient |
| topic_unstemmed |
ddc 610 bkl 44.40 bkl 44.38 misc Duodenal Ulcer misc Ranitidine misc Ulcer Recurrence misc Roxatidine misc Duodenal Ulcer Patient |
| topic_browse |
ddc 610 bkl 44.40 bkl 44.38 misc Duodenal Ulcer misc Ranitidine misc Ulcer Recurrence misc Roxatidine misc Duodenal Ulcer Patient |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Drugs |
| hierarchy_parent_id |
320609413 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Drugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)320609413 (DE-600)2021165-X |
| title |
Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers |
| ctrlnum |
(DE-627)SPR033150176 (SPR)00003495-198800353-00018-e |
| title_full |
Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers |
| author_sort |
Brunner, G. |
| journal |
Drugs |
| journalStr |
Drugs |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1988 |
| contenttype_str_mv |
txt |
| container_start_page |
102 |
| author_browse |
Brunner, G. |
| container_volume |
35 |
| class |
610 ASE 44.40 bkl 44.38 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Brunner, G. |
| doi_str_mv |
10.2165/00003495-198800353-00018 |
| dewey-full |
610 |
| title_sort |
roxatidine acetate in the long term maintenance of duodenal ulcers |
| title_auth |
Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers |
| abstract |
Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. |
| abstractGer |
Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. |
| abstract_unstemmed |
Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
Suppl 3 |
| title_short |
Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers |
| url |
https://dx.doi.org/10.2165/00003495-198800353-00018 |
| remote_bool |
true |
| ppnlink |
320609413 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00003495-198800353-00018 |
| up_date |
2024-07-03T16:55:06.105Z |
| _version_ |
1803577674805805056 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033150176</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519101046.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1988 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00003495-198800353-00018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033150176</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00003495-198800353-00018-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.38</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brunner, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Roxatidine Acetate in the Long Term Maintenance of Duodenal Ulcers</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1988</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary A non-comparative multicentre study of 105 patients with healed duodenal ulcers was conducted to determine the effect on ulcer recurrence of 6 months’ maintenance treatment with roxatidine acetate 75mg daily. All patients had previously received roxatidine acetate treatment. 31 patients out of 89 had 32 relapsed ulcers after 6 months of treatment, which represents an overall relapse rate of around 30%; the relapse rate in smokers was double that of non-smokers. The overall incidence of epigastric pain did not increase significantly over the period of the trial, although some patients complained of mild pain when they entered the study despite having endoscopically confirmed healed ulcers. At the end of the study continuous poor appetite and pyrosis were reported by 17% and 6% of patients, respectively. Side effects, which included constipation and diarrhoea, were reported by 4 patients, 1 of whom withdrew from therapy. There were no clinically significant changes in laboratory values. Thus, maintenance treatment with roxatidine acetate 75mg daily proved a safe and effective method of preventing symptomatic duodenal ulcer relapse.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Duodenal Ulcer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ranitidine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ulcer Recurrence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Roxatidine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Duodenal Ulcer Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Drugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1971</subfield><subfield code="g">35(1988), Suppl 3 vom: März, Seite 102-105</subfield><subfield code="w">(DE-627)320609413</subfield><subfield code="w">(DE-600)2021165-X</subfield><subfield code="x">1179-1950</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:1988</subfield><subfield code="g">number:Suppl 3</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:102-105</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00003495-198800353-00018</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.38</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">1988</subfield><subfield code="e">Suppl 3</subfield><subfield code="c">03</subfield><subfield code="h">102-105</subfield></datafield></record></collection>
|
| score |
7.400075 |